Neuroblastoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Neuroblastoma Clinical Trials Market Report Overview
There were a total of 680 neuroblastoma clinical trials conducted as of January 2023. The neuroblastoma clinical trial market research report provides a comprehensive overview of the market across regions and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. The report includes information about the sponsor types and the prominent sponsors associated with the trials as well.
Neuroblastoma Clinical Trials Market Segmentation by Regions
The key regions where neuroblastoma clinical trials are conducted are North America, Europe, Asia-Pacific, Middle East & Africa, and South & Central America. As of January 2023, North America accounted for the highest share of the regional landscape. Sponsors conducted more than 50% of the trials in this region.
Neuroblastoma Clinical Trials Analysis by Regions, 2023 (%)
Buy the Full Report for More Regional Insights into the Neuroblastoma Clinical Trials Market
Key Regions | · North America
· Europe · Asia-Pacific · Middle East & Africa · South & Central America |
Key Countries | · The US
· Canada · Australia · France · The UK |
Leading Sponsors | · Y-mAbs Therapeutics Inc
· Novartis AG · Bristol-Myers Squibb Co · F. Hoffmann-La Roche Ltd · Pfizer Inc |
Key Sponsor Types | · Company
· Institution · Government |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Neuroblastoma Clinical Trials Market Segmentation by Countries
- Country Insights
The US had the highest number of neuroblastoma clinical trials, as of January 2023. Meanwhile, Australia had the highest average patient enrollment as of January 2023.
- G7 Countries
Among the G7 (US, UK, Germany, France, Italy, Canada, and Japan) countries, Canada had the highest proportion of neuroblastoma to oncology clinical trials as of January 2023
- E7 countries
Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Turkey had the highest proportion of neuroblastoma to oncology clinical trials as of January 2023
Neuroblastoma Clinical Trials Analysis by Countries, 2023 (%)
Buy the Full Report for More Country Insights into the Neuroblastoma Clinical Trials Market
Neuroblastoma Clinical Trials Market - Competitive Landscape
A few of the leading sponsors associated with the market are:
- Y-mAbs Therapeutics Inc.
- Novartis AG
- Bristol-Myers Squibb Co
- Hoffmann-La Roche Ltd
- Pfizer Inc.
Y-mAbs Therapeutics Inc. conducted the highest number of neuroblastoma clinical trials as of January 2023.
Neuroblastoma Clinical Trials Market Analysis by Sponsors, 2023 (%)
Buy the Full Report for More Sponsor Insights into the Neuroblastoma Clinical Trials Market
Neuroblastoma Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the market are companies, institutions, and the government. Out of them, the institution segment dominated the market in January 2023.
Neuroblastoma Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
Buy the Full Report for More Sponsor Type Insights into the Neuroblastoma Clinical Trials Market
Segments Covered in the Report
Neuroblastoma Clinical Trials Regional Outlook (2023)
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South and Central America
Neuroblastoma Clinical Trials Country Outlook (2023)
- The US
- Canada
- Australia
- France
- The UK
Neuroblastoma Clinical Trials Regional Outlook (2023)
- Company
- Institution
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end-point status.
- The report reviews the top companies involved and enlists all trials about the company.
- The report provides all the unaccomplished trials with reasons for unaccomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies for investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
Novartis AG
Bristol-Myers Squibb Co
F. Hoffmann-La Roche Ltd
Pfizer Inc
Children’s Cancer and Leukaemia Group
APEIRON Biologics AG
United Therapeutics Corp
AstraZeneca Plc
GSK plc
Table of Contents
Table
Figures
Frequently asked questions
-
Which region accounted for the highest number of neuroblastoma clinical trials in January 2023?
North America accounted for the highest number of neuroblastoma clinical trials as of January 2023.
-
Which country conducted the highest number of neuroblastoma clinical trials in January 2023?
The US conducted the highest number of neuroblastoma clinical trials as of January 2023.
-
Which sponsor type was the most prominent in the neuroblastoma clinical trials in January 2023?
As of January 2023, the institution sponsor type conducted most of the neuroblastoma clinical trials.
-
Which are the leading sponsors of neuroblastoma clinical trials?
A few of the leading sponsors of neuroblastoma clinical trials are Y-mAbs Therapeutics Inc., Novartis AG, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd, and Pfizer Inc., among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.